- Home
- QURE vs IMNM Comparison
QURE vs IMNM Comparison
Compare QURE & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- IMNM
- Stock Information
- Founded
- QURE 1998
- IMNM 2006
- Country
- QURE Netherlands
- IMNM United States
- Employees
- QURE N/A
- IMNM 105
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- QURE Health Care
- IMNM Health Care
- Exchange
- QURE Nasdaq
- IMNM Nasdaq
- Market Cap
- QURE 691.2M
- IMNM 806.1M
- IPO Year
- QURE 2007
- IMNM 2020
- Fundamental
- Price
- QURE $12.84
- IMNM $9.52
- Analyst Decision
- QURE Strong Buy
- IMNM Strong Buy
- Analyst Count
- QURE 8
- IMNM 5
- Target Price
- QURE $39.43
- IMNM $28.60
- AVG Volume (30 Days)
- QURE 798.8K
- IMNM 1.2M
- Earning Date
- QURE 03-03-2025
- IMNM 03-27-2025
- Dividend Yield
- QURE N/A
- IMNM N/A
- EPS Growth
- QURE N/A
- IMNM N/A
- EPS
- QURE N/A
- IMNM N/A
- Revenue
- QURE $28,587,000.00
- IMNM $10,129,000.00
- Revenue This Year
- QURE $153.92
- IMNM N/A
- Revenue Next Year
- QURE N/A
- IMNM N/A
- P/E Ratio
- QURE N/A
- IMNM N/A
- Revenue Growth
- QURE N/A
- IMNM N/A
- 52 Week Low
- QURE $3.73
- IMNM $8.97
- 52 Week High
- QURE $19.18
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- QURE 38.20
- IMNM 40.66
- Support Level
- QURE $12.72
- IMNM $9.67
- Resistance Level
- QURE $14.42
- IMNM $10.68
- Average True Range (ATR)
- QURE 0.85
- IMNM 0.80
- MACD
- QURE -0.26
- IMNM -0.08
- Stochastic Oscillator
- QURE 7.26
- IMNM 0.34
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.